Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890971747> ?p ?o ?g. }
Showing items 1 to 56 of
56
with 100 items per page.
- W2890971747 abstract "7048 Background: AML is a disease of the elderly, and outcomes with standard treatment are dismal. Allogeneic transplant is the only curative therapy for most patients with AML. Recent work has shown age is not a factor in transplant outcomes, and should not be a limiting factor for transplant. The treatment pathway for older patients with AML should take into account their disease risk, comorbidities, and treatments with a proven survival advantage. We investigated our institutional experience to help guide the establishment of optimal pathways for patients. Methods: We conducted a retrospective analysis of 118 patients over age 65 with AML treated at our institution between 2010-2015. Patients receiving therapy (n = 90) were categorized into two groups: intensive induction therapy (7+3 based) or induction therapy with a hypomethylating agent. The groups were well matched in regard to comorbidities. Results: In poor risk patients, complete remission (CR) was achieved in 42% (n = 30/71). Select patients up to age 75 proceeded to allogeneic transplant if they achieved CR. Survival in CR1 was higher in the transplant (n = 22, median 719 days, 95% CI: 366-1071 days), than in the non-transplant group (n = 8, median 257 days, 95% CI: 92-421 days, p-value < .001). In analyzing all risk groups, overall survival was superior in transplant (median 1188 days) versus non-transplant recipients (median 185 days) (see 1, 2, and 3 year survival in table). No difference in median survival occurred based on age at induction (older than 70: n = 9, younger than 70: n = 16, p-value = 0.316). There was no difference in median survival based on chemotherapy regimen without transplant: intensive induction (n = 24, survival 250 days, p-value 0.179) compared to hypomethylating agents (n = 22, survival 139 days). Conclusions: We confirm that transplant can be safely performed in patients over 70 years of age, and highlight the survival advantage of transplant to chemotherapy alone. Additionally, our data found no survival benefit of hypomethylating agents in elderly patients with poor risk AML.[Table: see text]" @default.
- W2890971747 created "2018-09-27" @default.
- W2890971747 creator A5052079637 @default.
- W2890971747 creator A5070277385 @default.
- W2890971747 creator A5088234044 @default.
- W2890971747 date "2017-05-20" @default.
- W2890971747 modified "2023-09-27" @default.
- W2890971747 title "Allogeneic transplant leads to markedly improved survival in older patients with AML." @default.
- W2890971747 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.7048" @default.
- W2890971747 hasPublicationYear "2017" @default.
- W2890971747 type Work @default.
- W2890971747 sameAs 2890971747 @default.
- W2890971747 citedByCount "0" @default.
- W2890971747 crossrefType "journal-article" @default.
- W2890971747 hasAuthorship W2890971747A5052079637 @default.
- W2890971747 hasAuthorship W2890971747A5070277385 @default.
- W2890971747 hasAuthorship W2890971747A5088234044 @default.
- W2890971747 hasConcept C126322002 @default.
- W2890971747 hasConcept C143998085 @default.
- W2890971747 hasConcept C2779134260 @default.
- W2890971747 hasConcept C3019894029 @default.
- W2890971747 hasConcept C3020284061 @default.
- W2890971747 hasConcept C71924100 @default.
- W2890971747 hasConceptScore W2890971747C126322002 @default.
- W2890971747 hasConceptScore W2890971747C143998085 @default.
- W2890971747 hasConceptScore W2890971747C2779134260 @default.
- W2890971747 hasConceptScore W2890971747C3019894029 @default.
- W2890971747 hasConceptScore W2890971747C3020284061 @default.
- W2890971747 hasConceptScore W2890971747C71924100 @default.
- W2890971747 hasLocation W28909717471 @default.
- W2890971747 hasOpenAccess W2890971747 @default.
- W2890971747 hasPrimaryLocation W28909717471 @default.
- W2890971747 hasRelatedWork W2023561397 @default.
- W2890971747 hasRelatedWork W2036005343 @default.
- W2890971747 hasRelatedWork W2045144312 @default.
- W2890971747 hasRelatedWork W2068717819 @default.
- W2890971747 hasRelatedWork W2129692136 @default.
- W2890971747 hasRelatedWork W2157009217 @default.
- W2890971747 hasRelatedWork W2317778333 @default.
- W2890971747 hasRelatedWork W2319882281 @default.
- W2890971747 hasRelatedWork W2472888030 @default.
- W2890971747 hasRelatedWork W2558891317 @default.
- W2890971747 hasRelatedWork W2560068817 @default.
- W2890971747 hasRelatedWork W2560875521 @default.
- W2890971747 hasRelatedWork W2573340085 @default.
- W2890971747 hasRelatedWork W2589000699 @default.
- W2890971747 hasRelatedWork W2612501955 @default.
- W2890971747 hasRelatedWork W2756543884 @default.
- W2890971747 hasRelatedWork W2891363421 @default.
- W2890971747 hasRelatedWork W3090298178 @default.
- W2890971747 hasRelatedWork W3138897860 @default.
- W2890971747 hasRelatedWork W567063424 @default.
- W2890971747 isParatext "false" @default.
- W2890971747 isRetracted "false" @default.
- W2890971747 magId "2890971747" @default.
- W2890971747 workType "article" @default.